<DOC>
	<DOC>NCT02542605</DOC>
	<brief_summary>Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.</brief_summary>
	<brief_title>To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
	<criteria>Adults ≥ 18 to ≤ 45 years of age upon entry into screening History of migraine headaches without aura for ≥ 6 months prior to screening according to the IHS Classification ICHDII (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient selfreport Migraine frequency: ≥ 1 and ≤ 5 migraine days per month in each of the 3 months prior to screening History of migraine with aura, cluster headache or hemiplegic migraine headache according to the IHS Classification ICHDII (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient selfreport ≥ 6 migraine days per month in the last 3 months prior to study enrollment and during screening period Other headache disorders (except for episodic tensiontype headache &lt;5 days/month)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Migraine Headache</keyword>
	<keyword>Headache, Migraine</keyword>
	<keyword>Amgen</keyword>
</DOC>